石药集团(01093.HK) 公布，集团开发的带状疱疹mRNA疫苗产品SYS6017已获得国家药品监督管理局批准，可以在中国开展临床试验。
该产品由编码水痘-带状疱疹病毒(VZV)糖蛋白E(gE蛋白)的mRNA分子包裹于脂质纳米颗粒所构成，适用于预防带状疱疹的感染。临床前研究显示，该产品可有效诱导体液免疫和细胞免疫应答。安全性评价数据亦表明该产品具有良好的安全性，在临床研究上有望表现出较少的不良反应。
集团表示，近年来带状疱疹发病趋于年轻化，尤其是亚健康人群以及肿瘤、艾滋病患者等免疫力低下人群，患带状疱疹的风险显著增加，目前全球尚无针对VZV感染的mRNA疫苗上市，将全力推进该产品的临床研究工作，力争该产品尽快上市。(gc/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-07 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.